A Randomized, Double-Blind, Placebo-Controlled 52-Week Study to Assess
Research payments
$229,441
Through program year 2022, $229,441 in research payments was reported against A Randomized, Double-Blind, Placebo-Controlled 52-Week Study to Assess, across 117 payments, paid by GlaxoSmithKline, LLC..
- Paid by
- GlaxoSmithKline, LLC.
- ClinicalTrials.gov
- No trial number was reported for this study
By program year
4 rows| Year | Kind | Amount | Payments |
|---|---|---|---|
| 2022 | Research | $2,950 | 3 |
| 2021 | Research | $17,650 | 7 |
| 2020 | Research | $60,601 | 48 |
| 2019 | Research | $148,241 | 59 |
Breakdown
Usually the institution or organisation running the study, not a person.
Records
Every payment, record by record
Date, amount, who was paid and what for — filter by year and kind, or download as CSV, free, in files of 5,000 rows.
Principal investigators named
9 shownNamed on the study's payments. Being named is not being paid: the money in the figures above went to the recipients listed, not necessarily to these people.
- William Stohl Los Angeles, CA Named on 10 payments
- Ramesh Gupta Memphis, TN Named on 8 payments
- Laura Geraldino Pardilla New York, NY Named on 6 payments
- Andrew Hudnut Elk Grove, CA Named on 5 payments
- Laura Cruse Tampa, FL Named on 5 payments
- Suneet Grewal San Leandro, CA Named on 4 payments
- Vikas Majithia Jackson, MS Named on 4 payments
- Roger Diegel Kalispell, MT Named on 3 payments
- Ralph Bennett Phoenix, AZ Named on 3 payments
What you are looking at
Research payments are tied to a study. Being named on a study as a principal investigator is reported separately from being paid as a recipient, and the two are not the same thing — a named investigator has not necessarily received the money.